Health-related quality of life in HIV-1-infected patients on HAART: A five-years longitudinal analysis accounting for dropout in the APROCO-COPILOTE cohort (ANRS CO-8)

Quality of Life Research

Volumn 16, Issue 4, 2007, Pages 577-591

  Protopopescu, Camelia ^a,b   Marcellin, Fabienne ^a,b   Spire, Bruno ^a,b   Préau, Marie ^a,b   Verdon, Renaud ^c   Peyramond, Dominique ^d   Raffi, François ^e   Chêne, Geneviève ^a   Leport, Catherine ^f   Carrieri, Maria Patrizia ^a,b  

^a INSERM   (France)

^b OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^c CHU CÔTE DE NACRE   (France)

^d CROIX ROUSSE HOSPITAL   (France)

^e HÔTEL DIEU   (France)

^f EMI 0112 Faculte de Medecine Bichat   (France)

Author keywords

Dropout; HAART; Hepatitis C; HIV; Quality of life

Indexed keywords

PROTEINASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HEALTH STATUS; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUALITY OF LIFE; SELF REPORT; SHORT FORM 36;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FRANCE; HEALTH STATUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LONGITUDINAL STUDIES; MALE; MODELS, STATISTICAL; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT DROPOUTS; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; QUALITY OF LIFE; SICKNESS IMPACT PROFILE; TIME FACTORS; TREATMENT OUTCOME;

EID: 33947492387     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-006-9151-7     Document Type: Article

References (51)

1. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., Satten, G. A., et al. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine, 338, 853-860.
2. Little, R., & Rubin, D. (2002). Statistical analysis with missing data.
3. Laird, N. M. (1988). Missing data in longitudinal studies. Statistics in Medicine, 7, 305-315.
4. Vonesh, E. F., Greene, T.,&Schluchter, M. D. (2006). Shared parameter models for the joint analysis of longitudinal data and event times. Statistics in Medicine, 15, 143-163.
5. Hogan, J. W., Lin, X., & Herman, B. (2004). Mixtures of varying coefficient models for longitudinal data with discrete or continuous nonignorable dropout. Biometrics, 60, 854-864.
6. Lin, D. Y., & Ying, Z. (2003). Semiparametric regression analysis of longitudinal data with informative drop-outs. Biostatistics, 4, 385-398.
7. Hu, C., & Sale, M. E. (2003). A joint model for nonlinear longitudinal data with informative dropout. Journal of Pharmacokinetics and Pharmacodynamics, 30, 83-103.
8. Guo, X., & Carlin, B. P. (2004). Separate and joint modeling of longitudinal and event time data using standard computer packages. The American Statistician, 58, 1-9.
9. Carrieri, P., Spire, B., Duran, S., Katlama, C., Peyramond, D., Francois, C., et al. (2003). Health-related quality of life after 1 year of highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 32, 38-47.
10. Carrieri, M. P., Leport, C., Protopopescu, C., Cassuto, J. P., Bouvet, E., Peyramond, D., et al. (2006), Factors associated with nonadherence to highly active antiretroviral therapy: A 5-year follow-up analysis with correction for the bias induced by missing data in the treatment maintenance phase. Journal of Acquired Immune Deficiency Syndromes, 41, 477-485.
11. Ware, J. E., Jr., & Sherbourne, C. D. (1992). The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Medical Care, 30, 473-483.
12. McHorney, C. A., Ware, J. E., Jr., & Raczek, A. E. (1993). The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Medical Care, 31, 247-263.
13. McHorney, C. A., Ware, J. E., Jr., Lu, J. F.,&Sherbourne, C. D. (1994). The MOS 36-item Short-Form Health Survey (SF-36): III Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Medical Care, 32, 40-66.
14. Ware, J. E., Jr., Keller, S. D., Gandek, B., Brazier, J. E., & Sullivan, M. (1995). Evaluating translations of health status questionnaires. Methods from the IQOLA project. International Quality of Life Assessment. International Journal of Technology Assessment in Health Care, 11, 525-551.
15. Leplege, A., Mesbah, M., & Marquis, P. (1995). [Preliminary analysis of the psychometric properties of the French version of an international questionnaire measuring the quality of life: The MOS SF-36 (version 1.1)]. Revue d Epidemiologie et de Sante Publique, 43, 371-379.
16. Prentice, R. L., & Gloeckler, L. A. (1978). Regression analysis of grouped survival data with application to breast cancer data. Biometrics, 34, 57-67.
17. Henderson, R., Diggle, P., & Dobson, A. (2000). Joint modelling of longitudinal measurements and event time data. Biostatistics, 1, 465-480.
18. SAS/STAT 9.1 (2004). User's Guide. Cary, NC, SAS Institute Inc: SAS Publishing.
19. Furher, R., & Rouillon, F. (1989). La version française de l'échelle CES-D. Description and translation of the auto-evaluation (in French). Psychiatrie et Psychobiologie, 4, 163-166.
20. Bissell, D., Paton, A., & Ritson, B. (1982). ABC of alcohol. Help: Referral. British Medical Journal (Clinical Research Ed), 284, 495-497.
21. Nieuwkerk, P. T., Gisolf, E. H., Colebunders, R., Wu, A. W., Danner, S. A., & Sprangers, M. A. (2000). Quality of life in asymptomatic- and symptomatic HIV infected patients in a trial of ritonavir/saquinavir therapy. The Prometheus Study Group. Acquired Immune Deficiency Syndromes, 14, 181-187.
22. Cohen, C., Revicki, D. A., Nabulsi, A., Sarocco, P. W., & Jiang, P. (1998). A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group. Acquired Immune Deficiency Syndromes, 12, 1495-1502.
23. Carr, A., Chuah, J., Hudson, J., French, M., Hoy, J., Law, M., et al. (2000). A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection: The OzCombo1 study. Acquired Immune Deficiency Syndromes, 14, 1171-1180.
24. Nieuwkerk, P. T., Gisolf, E. H., Reijers, M. H., Lange, J. M., Danner, S. A., & Sprangers, M. A. (2001). Long-term quality of life outcomes in three antiretroviral treatment strategies for HIV-1 infection. Acquired Immune Deficiency Syndromes, 15, 1985-1991.
25. Burgoyne, R. W., Rourke, S. B., Behrens, D. M., & Salit, I. E. (2004). Long-term quality-of-life outcomes among adults living with HIV in the HAART era: The interplay of changes in clinical factors and symptom profile. Acquired Immune Deficiency Syndromes Behavior, 8, 151-163.
26. Burgoyne, R., & Renwick, R. (2004). Social support and quality of life over time among adults living with HIV in the HAART era. Social Science and Medicine, 58, 1353-1366.
27. Eriksson, L. E., Bratt, G. A., Sandstrom, E., & Nordstrom, G. (2005). The two-year impact of first generation protease inhibitor based antiretroviral therapy (PI-ART) on health-related quality of life. Health Quality of Life Outcomes, 3, 32.
28. Campsmith, M. L., Nakashima, A. K., & Davidson, A. J. (2003). Self-reported health-related quality of life in persons with HIV infection: Results from a multi-site interview project. Health Quality of Life Outcomes, 1, 12.
29. Jia, H., Uphold, C. R., Wu, S., Chen, G. J., & Duncan, P. W. (2005). Predictors of changes in health-related quality of life among men with HIV infection in the HAART era. Acquired Immune Deficiency Syndromes Patient Care STDS Patient Care STDS, 19, 395-405.
30. Hogg, R. S., Yip, B., Chan, K. J., Wood, E., Craib, K. J., O'Shaughnessy, M. V., & Montaner, J. S. (2001). Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA, 286, 2568-2577.
31. Bonfanti, P., Valsecchi, L., Parazzini, F., Carradori, S., Pusterla, L., Fortuna, P., et al. (2000). Incidence of adverse reactions in HIV patients treated with protease inhibitors: a cohort study Coordinamento Italiano Studio Allergia e Infezione da HIV (CISAI) Group. Journal of Acquired Immune Deficiency Syndromes, 23, 236-245.
32. Fellay, J., Boubaker, K., Ledergerber, B., Bernasconi, E., Furrer, H., Battegay, M., et al. (2001). Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study. Lancet, 358, 1322-1327.
33. Ammassari, A., Murri, R., Pezzotti, P., Trotta, M. P., Ravasio, L., De Longis, P., et al. (2001). Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. Journal of Acquired Immune Deficiency Syndromes, 28, 445-449.
34. Duran, S., Spire, B., Raffi, F., Walter, V., Bouhour, D., Journot, V., et al. (2001). Self-reported symptoms after initiation of a protease inhibitor in HIV-infected patients and their impact on adherence to HAART. HIV Clinical Trials, 2, 38-45.
35. Bury, M. (1991). The sociology of chronic illness: A review of research and prospects. Sociology of Health and Illness, 13, 451-468.
36. Foster, G. R., Goldin, R. D., & Thomas, H. C. (1998). Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology, 27, 209-212.
37. Rodger, A. J., Jolley, D., Thompson, S. C., Lanigan, A., & Crofts, N. (1999). The impact of diagnosis of hepatitis C virus on quality of life. Hepatology, 30, 1299-1301.
38. Preau, M., Leport, C., Salmon-Ceron, D., Carrieri, P., Portier, H., Chene, G., et al. (2004). Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment. Acquired Immune Deficiency Syndromes Care, 16, 649-661.
39. Cederfjall, C., Langius-Eklof, A., Lidman, K., & Wredling, R. (2001). Gender differences in perceived health-related quality of life among patients with HIV infection. Acquired Immune Deficiency Syndromes Patient Care STDS, 15, 31-39.
40. Mrus, J. M., Williams, P. L., Tsevat, J., Cohn, S. E., & Wu, A. W. (2005). Gender differences in health-related quality of life in patients with HIV/AIDS. Quality of Life Research, 14, 479-491.
41. Nicholas, P. K., Kirksey, K. M., Corless, I. B., & Kemppainen, J. (2005). Lipodystrophy and quality of life in HIV: Symptom management issues. Applied Nursing Research, 18, 55-58.
42. Collins, E., Wagner, C., & Walmsley, S. (2000). Psychosocial impact of the lipodystrophy syndrome in HIV infection. Acquired Immune Deficiency Syndromes Read, 10, 546-550.
43. Préau, M., Bouhnik, A., Spire, B., Leport, C., Saves, M., Pïcard, O., et al. (2006). Health related quality of life and lipodystrophy syndrome among HIV-infected patients. Encephale, 32, 713-719.
44. Hsiung, P. C., Fang, C. T., Chang, Y. Y., Chen, M. Y., Wang, J. D. (2005). Comparison of WHOQOLbREF and SF-36 in patients with HIV infection. Quality of Life Research, 14, 141-150.
45. Monnete, G., Shao, Q., & Kwan, E. (2002). A first look at multilevel models. In S.C.S. Institute for Social Research. York University: Institute for Social Research. Statistical Consulting Service, York University.
46. Allison, P. D. (1995). Survival analysis using the SAS system: A practical guide. The SAS Institute, Cary, NC.
47. Allison, P. D. (1982). Discrete-time methods for the analysis of event histories. Sociological Methodology, 15, 61-98.
48. Jenkins, S. P. (1995). Easy estimation methods for discrete-time duration models. Oxford Bulletin of Economics and Statistics, 57, 129-138.
49. Jenkins, S. P. (1997). Estimation of discrete time (grouped duration data) proportional hazards models: pgmhaz. Stata Technical Bulletin Reprints, STB 17, 1-12.
50. Jenkins, S. P. (2005). Survival analysis. In Institute for Social and Economic Research, University of Essex.
51. Zewotir, T., & Galpin, J. S. (2005). Influence diagnostics for linear mixed models. Journal of Data Science, 3, 153-177.